Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma

doi:10.4251/wjgo.v15.i1.1

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4926)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

265

WORD

HTML

2736

Figures (1-1)

381

Tables (1-3)

327

Sum=3757

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

158

Download

462

Sum=620

Publishing Process of This Article

Item

Count

Browse

157

Download

392

Sum=549

Jan 15, 2023 (publication date) through Dec 23, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Oncol. Jan 15, 2023; 15(1): 1-18
Published online Jan 15, 2023. doi: 10.4251/wjgo.v15.i1.1

Table 3 Ongoing clinical trials investigating systemic therapy and/or local regional therapy against hepatocellular carcinoma

Clinical trials number	Study type	Agent(s)	Local regional therapy	Estimated enrollment	Primary endpoint
chiCTR2100044057	Phase II	Camrelizumab + Bevacizumab	Microwave Ablation	30	PFS
chiCTR2100046533	Prospective	Apatinib + Camrelizumab	TACE	37	PFS
NCT05162898	Prospective	Toripalimab + Lenvatinib	Radiofrequency Ablation	90	PFS
NCT05010434	Phase II	Sintilimab + Bevacizumab	Radiofrequency Ablation		ORR
NCT05444478	Prospective	Lenavatinib	Microwave Ablation	274	3-yr PFS%
NCT05277675	Prospective	Tislelizumab/Sintilimab + Lenvatinib/Bevacizumab	Radiofrequency Ablation	160	1-yr PFS%
NCT05162898	Prospective	Toripalimab + Lenvatinib	Radiofrequency ablation	90	RFS
NCT04663035	Phase II	Tislelizumab	Ablation	120	1-yr PFS%
NCT05355155	Phase II	Bevacizumab + Biosimilar IBI305	-	15	ORR
NCT05103904	Phase II	Lenvatinib	-	19	ORR
NCT04615143	Prospective	Tislelizumab/Tislelizumab + Levatinib	-	80	PFS
NCT04564313	Phase I	Camrelizumab	-	20	ORR
NCT04237740	Phase III	Relenvatinib	-	40	3-yr PFS%
NCT04204850	Phase II	Cabozantinib		20	DCR

DCR: Disease control rates; ORR: Objective response rates; PFS: Progression-free survival; RFA: Radiofrequency ablation; RFS: Relapse-free survival; TACE: Transhepatic arterial chemoembolization.

Citation: Liang J, Bai Y, Ha FS, Luo Y, Deng HT, Gao YT. Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma. World J Gastrointest Oncol 2023; 15(1): 1-18
URL: https://www.wjgnet.com/1948-5204/full/v15/i1/1.htm
DOI: https://dx.doi.org/10.4251/wjgo.v15.i1.1